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Abstract
Adults older than 65 years undergo more than 120,000 coronary artery bypass (CAB) procedures 
each year in the United States. Chronological age alone, though commonly used in prediction 
models of outcomes after CAB, does not alone reflect variability in aging process; thus, the risk of 
complications in older adults. We performed a prospective study to evaluate a relationship 
between senescence marker p16INK4a expression in peripheral blood T-lymphocytes (p16 levels in 
PBTLs) with aging and with perioperative outcomes in older CAB patients. We included 55 
patients age 55 and older, who underwent CAB in Johns Hopkins Hospital between September 1st, 
2010 and March 25th, 2013. Demographic, clinical and laboratory data following outline of the 
Society of Thoracic Surgeons data collection form was collected, and p16 mRNA levels in PBTLs 
were measured using Taqman® qRT-PCR. Associations between p16 mRNA levels in PBTLs 
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with length of hospital stay, frailty status, p16 protein levels in the aortic and left internal 
mammary artery tissue, cerebral oxygen saturation, and augmentation index as a measure of 
vascular stiffness were measured using regression analyses. Length of hospital stay was the 
primary outcome of interest, and major organ morbidity, mortality, and discharge to a skilled 
nursing facility were secondary outcomes. In secondary analysis, we evaluated associations 
between p16 mRNA levels in PBTLs and interleukin-6 levels using regression analyses. Median 
age of enrolled patients was 63.5 years (range 56-81 years), they were predominantly male 
(74.55%), of Caucasian descent (85.45%). Median log2(p16 levels in PBTLs) were 4.71 (range 
1.10-6.82). P16 levels in PBTLs were significantly associated with chronological age (mean 
difference 0.06 for each year increase in age, 95% CI 0.01-0.11) and interleukin 6 levels (mean 
difference 0.09 for each pg/ml increase in IL-6 levels, 95% CI 0.01-0.18). There were no 
significant associations with frailty status, augmentation index, cerebral oxygenation and p16 
protein levels in blood vessels. Increasing p16 levels in PBTLs did not predict length of stay in the 
hospital (HR 1.10, 95% CI 0.87-1.40) or intensive care unit (HR 1.02, 95% CI 0.79-1.32). 
Additional evaluation of p16 levels in PBTLs as predictor of perioperative outcomes is required 
and should include additional markers of immune system aging as well as different outcomes after 
CAB in addition to length of hospital stay.
Keywords
coronary artery bypass; chronological age; aging biomarker; senescence; p16INK4a levels; 
peripheral blood T-lymphocytes; frailty; length of hospital stay
1. Introduction
Coronary artery bypass (CAB) is among the most commonly performed surgical procedures 
in older adults, involving over 120,000 patients older than 65 years in the United States 
alone (Go 2014) 1. Models which predict length of hospital and Intensive Care Unit (ICU) 
stay after cardiac surgery commonly incorporate chronological age (Janssen 2004, Ghotkar 
2006, 1 Messaoudi 2009) 2-4. Unfortunately, chronological age does not accurately predict 
an individual's aging process and decline in physiologic reserve that can be accelerated or 
retarded in response to environmental exposures, host experiences, and genetics (Mitnitski 
2002) 5(Fried 1998) 6; therefore, identification and utilization of ‘aging biomarkers’ that 
accurately measure patients’ physiologic reserve is an important clinical need.
Aging is characterized by a reduction in the regenerative capacity of many tissues, and the 
accumulation of senescent cells appears to broadly contribute to tissue aging (Wagers 2005, 
Janzen 2006, Sharpless 2007, Rodier 2011) 7-10. Cellular senescence is an irreversible 
growth arrest (Hayflick 1965) 11 that occurs in response to a variety of noxious stimuli (e.g., 
DNA damage, telomere shortening, oxidative stress, and epigenetic damage) (Wright 2002, 
Kirkwood 2005, Kuilman 2010) 12-14. Senescent cells do not replicate, which impairs tissue 
homeostasis (Drummond-Barbosa 2008) 15, and secrete pro-inflammatory cytokines (Coppe 
2010) 16, associated with age-associated phenotypes such as sarcopenia, immune 
dysfunction and delayed wound healing (Ashcroft 2002) 17. Therefore, measuring the 
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accumulation of senescent cells in vivo has been suggested to provide a means of measuring 
the ‘molecular age’ of the organism.
The p16INK4a senescence marker has been suggested to serve as a biomarker of aging and 
predictor of physiologic reserve (Dimri 2004, Sharpless 2007) 8,18. Expression of p16INK4a 
is not detected in young cells, but is potently activated by stress factors that promote cellular 
senescence (Brenner 1998, te Poele 2002, Kim 2006, Song 2010) 19-22. Senescent cells 
remain in tissues indefinitely; therefore, accumulation of p16INK4a expression reflects the 
accumulation of senescent cells with aging and as such, expression of p16INK4a is intrinsic 
to the aging process. Expression of the p16INK4a transcript is highly dynamic, increasing 
exponentially with chronologic age in all mammalian species tested to date (Zindy 1997, 
Melk 2003; Krishnamurthy 2004) 23-25. The ability of p16INK4a in human kidney allograft 
biopsies predicts kidney function based on creatinine level at 6 month and 1 year post-
transplant and performs better than telomere length (McGlynn 2009; Koppelstaetter 2008; 
Gingell-Littlejohn 2013) 26-28. Interestingly, in humans, expression of p16INK4a in 
peripheral blood T-lymphocytes (PBTL) changes >10-fold (Liu 2009) 29 throughout 
lifespan. Additionally, p16INK4a expression in PBTL shows a much stronger correlation 
with chronologic age than do other aging biomarkers (Liu 2009) 29 (r2 0.6-0.7 for p16INK4a, 
r2<0.2 for leukocyte telomere length or IL-6). While the role of p16INK4a as a molecular age 
biomarker is becoming established, the clinical utility of measuring p16INK4a levels to 
predict clinically-relevant outcomes is not well described, though promising as demonstrated 
by previous work in kidney transplantation.
In this prospective pilot study of older adults undergoing CAB procedure, we asked two 
questions: can p16INK4a expression serve as a biomarker of aging in this patient population; 
and can p16INK4a levels predict poor clinical outcomes. We hypothesized that older adults 
have higher levels of p16INK4a, and that p16INK4a mRNA levels in PBTLs correlates with 
other markers of aging including frailty, p16 protein levels in vascular walls, cerebral 
oxygen saturation and measures of vascular stiffness. We further hypothesized that patients 
with higher p16INK4a mRNA levels in PBTLs have a slower recovery, and therefore are 
more likely to have increased length of hospital stay, compared to patients with lower 
p16INK4a mRNA levels in PBTLs.
2. Material and Methods
2.1. Institutional Review Board
The Johns Hopkins Medicine Institutional Review Board (IRB) approved the study 
NA_00032660.
2.2. Study Design and Setting
We have conducted a prospective study of older adults undergoing CAB procedure in urban, 
academic, tertiary care hospital (Johns Hopkins Hospital). All participants were recruited 
between September 1st, 2010 and March 25th, 2013 and followed for 30 days after their 
surgical procedure.
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2.3. Subjects
We have included all patients 55 years of age and older undergoing primary elective or 
urgent CAB surgery. We have excluded patients requiring emergency or salvage CAB 
surgery, being reoperated, undergoing combined, aortic or valvular surgical procedures, 
primary ventricular assist device implantation, having any acute illness other than coronary 
artery disease, or requiring preoperative inotropic or vasoactive medications. We adjusted 
our inclusion/ exclusion criteria after initial slow recruitment rate as follows: minimal age of 
participants was decreased from 65 to 55, and exclusions such as ejection fraction less than 
40% and participation in other research protocols were removed.
All patients scheduled to undergo CAB surgical procedure were identified through the 
operating room schedule. We then screened electronic medical records of all identified 
patients for inclusion/ exclusion criteria. Eligible patients were approached by the research 
personnel either in the pre-operative clinic or at the bedside in the hospital at least one day 
prior to the scheduled surgical procedure. The patient's surgical attending physician was 
notified of the patient's enrollment into the study. All study participants provided informed 
consent on their participation in the study.
2.4. Study Procedures
Upon enrollment we collected the following participant's information: demographic 
characteristics of age, gender, race; anthropomorphic characteristics of weight, height and 
body mass index (BMI); smoking, exercise and alcohol consumption; organ system diseases 
through self-report and chart review; current medications; functional capacity including 
basic and instrumental activities of daily living (ADLs (Katz 1970) 30 and IADLs (Lawton 
1969) 31), ability to drive; laboratory data reflecting major organ system function (white cell 
count, hemoglobin level, platelets, blood urea nitrogen, creatinine, albumin, alkaline 
phosphatase, total bilirubin and calcium levels, international normalized ratio), heart rate 
and myocardial ejection fraction. Comorbidities burden was summarized by Charlson index 
(Charlson 1987) 32We then performed following measurements: frailty assessment, vascular 
stiffness, p16INK4a levels in PBTLs and vascular wall, interleukin 6 (IL-6) levels in serum, 
and ScO2.
2.4.1. Frailty Assessment—Frailty assessment was performed pre-operatively following 
methodology previously described (Fried 1998) 33. Briefly, frailty was measured using a 
previously validated scoring system evaluating 5 domains: (1) shrinking defined as 
unintentional weight loss of 10 pounds or more in the last year; (2) weakness determined by 
a grip-strength test and adjusted for gender and body mass index (BMI); (3) exhaustion as 
measured by two questions from the modified 10-item Center for Epidemiological Studies-
Depression scale; (4) low physical activity as measured by a version of the Minnesota 
Leisure Time Activities Questionnaire (Taylor 1978) 34; and (5) slowed walking speed as 
measured by averaging three trials of walking 15 feet at a normal pace. Each domain yielded 
a dichotomous score of 0 or 1. Patients were categorized based on their total score into frail 
(total score 3-5), prefrail (total score 1-2), and nonfrail (total score 0).
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2.4.2. Vascular Stiffness—Vascular stiffness was assessed preoperatively by measuring 
pulse pressure (PP) based on oscillometric blood pressure measurement averaged over 3 
repeated measurements and augmentation index (AI) obtained non-invasively by 
applanation tonometry (SPT-301, Millar, Inc., Houston, TX) from the radial artery. AI was 
calculated using a software package (SphygmoCor, Atcor Medical, West Ryde, NSW, 
Australia) to perform arterial waveform analysis, and expressed in %.
2.4.3. p16INK4a mRNA Expression Levels in PBTLs—We collected venous blood for 
p16INK4a expression in PBTLs either during the pre-operative visit to the clinic concomitant 
with routine blood draw or intraoperatively after induction of general anesthesia prior to 
surgical incision. Blood processing occurred in two steps. The 1st step was performed in the 
OAIC (Older Americans Independence Center) Molecular Genetics Core laboratory. 
Enriched T-cells, pelleted cells for future DNA analysis and plasma were obtained by cell 
sorting using the RosettSep™ kit (STEMCELL Technologies, Inc., Vancouver, BC, 
Canada) during this step. For complete description of the procedure please see Appendix 
6.1. All fractions were stored frozen. Specimens were shipped later in bulk to the reference 
laboratory at the University of North Carolina, Chapel Hill, NC. RNA was prepared from 
PBTLs and expression of p16INK4a mRNA transcripts was determined using Taqman® qRT-
PCR as per reference laboratory protocol 29. Briefly, total RNA was isolated using RNeasy 
Mini kit (QIAGEN, Hilden, Germany), mRNA was reverse transcribed into cDNA using 
ImProm-II reverse transcription system (Promega Corp., Madison, WI). Expression of 
p16INK4a was measured by real time qPCR using custom TaqMan® primers and normalized 
to two housekeeping genes. T cell isolation was assessed by measuring expression of CD3 
receptor. In all cases, Ct values ≥37 were considered background.
2.4.4. IL-6 Levels—IL-6 levels in serum were analyzed in the OAIC Molecular Genetics 
Core laboratory by human IL-6 immunoassay (High Sensitivity Quantikine ELISA kit, R&D 
Systems, Minneapolis, MN).
2.4.5. ScO2—The baseline value of ScO2 while on room air was collected in the operating 
room as soon as INVOS™ cerebral oximeter (Somanetics Corp., Troy, MI) was placed on 
the patient's forehead. The lowest value between the right and left sides was recorded at this 
time.
2.4.6. Vascular Wall p16INK4a Protein Levels—In patients requiring left internal 
mammary artery (LIMA) for revascularization, the portion of the artery discarded during 
trimming of the vessel was collected for p16INK4a quantification in the vessel wall. Aortic 
punches, removed and discarded during anastomoses of the venous grafts to the aorta, were 
also collected for p16INK4a quantification in the aortic wall. The OAIC Molecular Genetics 
Core laboratory analyzed p16INK4a protein levels in the vascular wall by Western blotting 
following previously described method (Werner 2009) 35. Briefly, flash frozen tissues were 
homogenized in Tris/Glycerol lysis buffer containing 4% SDS and protease inhibitors. 
Soluble fraction was resolved on SDS-PAGE gel and transferred to nitrocellulose 
membrane. Following the transfer of proteins to the nitrocellulose, the membrane was 
blocked for two hours in SuperBlock blocking reagent (Thermo Scientific, Inc.). Two hour 
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primary and secondary antibody incubations were performed in 10% SuperBlock in Tris 
buffered saline containing 0.05% Tween-20. The dilution of the p16 (F-12) primary 
antibody (Santa Cruz Biotechnology, Inc., Dallas, TX) was 1:250 while a 1:10,000 
secondary antibody (goat anti-mouse IgG conjugated to HRP) was employed. 
Chemiluminescent signal was developed using SuperSignal West Dura reagents following 
the manufacturer's protocol (Thermo Fisher Scientific, Inc., Waltham, MA). The bands were 
digitally captured using a Gel Logic 220 Imaging System (CareStream Health, Inc., 
Rochester, NY). Band intensity was quantified using NIH Image version 1.46, where 
background levels were subtracted from band signals using integrated adjacent pixels. The 
representative blot is demonstrated in Figure 1. For complete description of methodology 
please see Appendix 6.2.
2.5. Patient Care
Anesthesia, surgical procedures, intensive care unit (ICU) and hospital care of the patients 
were conducted according to current hospital protocols. We had no specific requirements as 
to the conduct of anesthesia, surgical procedure and postoperative care. Briefly, 
intraoperative care was conducted as follows: all patients received general anesthesia and 
were placed on cardiopulmonary bypass (CPB) for CAB procedure. Induction of anesthesia 
was performed with a combination of midazolam and fentanyl; vecuronium was given for 
muscle relaxation. Isoflurane was used for anesthesia maintenance during the case. 
Mechanical ventilation goal was to maintain normocapnia during surgery. Heparin (350 
IU/kg) was used for anticoagulation, which was monitored by the kaolin-activated clotting 
time and maintained at a level of >480 seconds during CPB. The extracorporeal circuit 
consisted of roller pumps (Terumo, Tokyo, Japan), a hollow fiber membrane oxygenator 
(Sorin, Milan, Italy), and a standard arterial line filter (Sorin, Milan, Italy). The priming 
consisted of 1600 mL of lactated Ringer's solution and a retrograde autologous prime of 700 
mL. CPB pump flow was adjusted to 1.8-2.2 L/m2/min. Nasopharyngeal temperature during 
CPB was maintained at 32°C, followed by rewarming to a urinary bladder temperature 
>=35°C. After the termination of CPB, heparin was neutralized by protamine. Propofol 
infusion was initiated at the end of the case and used for sedation during transport and in 
ICU until extubation.
2.6. Outcome Measures
Information about intraoperative course, major morbidities and mortality, length of ICU and 
hospital stay were collected following Society of Thoracic Surgeons (STS) adult cardiac 
surgery database worksheet outline 36. Patients were followed for the duration of hospital 
stay; if they were discharged prior to day 30 they received a follow-up phone call on day 30. 
The hospital follow-up was provided by daily evaluation of patients’ electronic medical 
records and interviews with care providers whenever insufficient documentation was 
present. Our primary outcome of interest was time to hospital discharge. We also followed 
patients for secondary outcomes: time to ICU discharge, hospital and 30-day all cause 
mortality, neurologic, pulmonary, cardiac, renal and composite major morbidity, functional 
recovery expressed as time to extubation, time to out-of-bed and need for physical therapy, 
need for reoperation, infection, blood use in perioperative period, and mesenteric and acute 
limb ischemia. We additionally collected data on discharge disposition. All data were 
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entered in a database developed by using online tool ASP.NET (Microsoft Corp., Redmond, 
WA), and maintained using SQL Server (Microsoft Corp., Redmond, WA) by the Division 
of Geriatric Medicine and Gerontology in the Department of Medicine, Johns Hopkins 
School of Medicine.
2.7. Power Calculation
For the purpose of power calculation we arbitrarily assumed low versus high levels of 
log2(p16INK4a mRNA in PBTLs) as being separated at the median, since we did not know 
what the precise values of p16INK4a in PBTLs would be in our population. For the primary 
outcome of total hospital length of stay, assuming alpha=0.05, power=80%, and a 20% 
increase in length of stay, 29 patients would be needed in each group, i.e. those who have 
low vs. high levels of p16 INK4a in PBTLs. This was based on a theoretical and conservative 
estimate, with a length of stay of 7 days in the group with low levels of p16 INK4a in PBTLs 
(S.D.=2 days) versus the group with high levels of p16 INK4a in PBTLs, with a length of stay 
of 8.5 days (20% greater, S.D.=2 days). Ultimately our primary analyses included 47 
patients on whom p16INK4a mRNA in PBTLs were successfully measured: for this sample 
size, a 24% increase in length of stay is detectable with power=80%.
2.8. Statistical Analyses
We performed exploratory data analyses by constructing stem and leaf plots for continuous 
variables, and frequency tabulation for categorical variables. We then created a scatter plot 
matrix for all continuous variables and side-by-side box plots of the p16INK4a levels in 
PBTLs by all the categorical variables. P16INK4a level in PBTLs were log2(p16INK4a)-
transformed. We then conducted a linear regression of a) p16INK4a protein levels in LIMA 
and b) aorta, c) vascular stiffness as expressed by AI, and d) ScO2 on p16INK4a mRNA 
levels in PBTLs (each separately), and a multinomial logistic regression of frailty status on 
p16INK4a mRNA levels in PBTLs, as well as these analyses adjusted for age. For the age-
adjusted analyses, we evaluated adjusted variable plots for the main predictors to ensure that 
that the findings were consistent with the data. In secondary analyses we conducted a linear 
regression of IL-6 levels on p16INK4a mRNA levels in PBTLs and performed multivariable 
regression based on previously described associations of p16INK4a mRNA levels in PBTLs 
with chronologic age, smoking, exercise and IL-6 levels as covariates29. Finally, we 
conducted a Cox regression of length of hospital stay (days) and ICU stay (hours) on 
p16INK4a levels in PBTLs, adjusting for chronologic age, frailty status and Charlson 
comorbidity index. For length of hospital stay (days) and ICU stay (hours) we additionally 
performed sensitivity analyses: by categorizing p16INK4a levels in PBTLs into 2 groups – 
less than 4.71 (median level) and equal or greater than 4.71 relative levels; by censoring the 
longest hospital discharge day at 15 days and ICU discharge hour at 122 hours (to assess 
influence of the outlying points).
3. Results
3.1. Study Flow
262 patients were screened for inclusion into the study, 178 were qualified to participate 
based on initial screening, 60 patients were enrolled, and 55 patients were analyzed (figure 
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1). Among 55 patients, 47 patients had completed analysis of p16INK4a levels in PBTLs. 2 
patients were lost to 30 days follow-up. 45 out of 55 CAB procedures were performed by the 
same surgeon.
3.2. Participants
Baseline patient characteristics, clinical and laboratory data as well as length of stay in the 
ICU and hospital postoperatively are presented in Table 1. The median age of participants 
was 63.5 years, with range 56-81 years. They were predominantly male (74.55%) of 
Caucasian origin (85.45%), representative of CAB patient population (Go 2014) 1. The 
median p16INK4a mRNA level in PBTLs was 4.71 (range 1.10-6.82). The levels of p16 
protein in LIMA were significantly lower than in aorta as reflected by ratio of p16 protein in 
LIMA/ p16 protein in aorta 0.49 (range 0.21-1.05), p<0.0001 for the difference. Median 
IL-6 levels were 2.66 (range 0.59-18.48) pg/ml. 10 (18.18%) of patients were not frail, 28 
(50.91%) were pre-frail and 17 (30.91%) were frail. Median duration of hospital stay was 6 
(range 3-27) days, and median duration of ICU stay was 33 (range 7-174) hours.
3.3. Baseline expression of p16INK4a mRNA levels in PBTLs and aging
To test our hypothesis that p16INK4a mRNA levels in PBTLs is an aging biomarker in this 
patient population, we explored association of p16INK4a mRNA levels in PBTLs with 
markers of aging identified for a priori analyses (chronologic age, p16 protein level in 
LIMA/ p16 protein level in aorta ratio, AI and ScO2) and secondary analyses (interleukin 6, 
smoking and exercise). In a priori analyses expression of p16 in PBTL was associated with 
chronological age only (for every year increase in age p16INK4a mRNA levels in PBTLs 
increase by 0.07, 95% CI 0.02-0.12, p<0.05) and was not associated with p16 protein level 
in LIMA/ p16 protein level in aorta ratio, AI and ScO2. In secondary analyses p16INK4a 
mRNA levels in PBTLs were associated with IL-6 protein levels (for every pg/ml increase 
in IL-6 protein level p16INK4a mRNA levels in PBTLs increase by 0.11, 95% CI 0.03-0.20, 
p<0.05 on univariate analysis, and increase by 0.09, 95% CI 0.01-0.18, p<0.05 on 
multivariable analysis). P16INK4a mRNA levels in PBTLs were not associated with smoking 
or exercise. Univariate and multivariate analyses data are summarized in Table 2.
3.4. P16INK4a mRNA levels in PBTLs and frailty
There were no significant associations between p16INK4a mRNA levels in PBTLs and frailty 
(Figure 3). The lack of association between p16INK4a mRNA levels in PBTLs and frailty 
remained after adjustment for chronological age (RRR 1.06, 95% CI 0.53-2.12, p=0.87 
when comparing pre-frail to non frail; RRR 0.78, 95% CI 0.38-1.60, p=0.51 when 
comparing frail to non frail) (Table 3).
3.5. P16INK4a mRNA levels in PBTLs and length of hospital and ICU stay
Median length of stay in the hospital was 6 days with the range 3-27 days, and median 
length of stay in the ICU was 33 hours with the range 7-174 hours. There was no association 
between p16INK4a mRNA levels in PBTLs and length of hospital stay (HR 1.10 for each one 
unit increase in p16INK4a mRNA levels in PBTLs, 95% CI 0.87-1.40, p=0.49), or length of 
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ICU stay (HR 0.98 for each unit increase in p16INK4a mRNA levels in PBTLs, 95% CI 
0.74-1.28, p=0.87) as further described in table 4.
3.6. Sensitivity analyses
When we categorized patients according to their p16INK4a mRNA levels in PBTLs into 2 
groups based on median levels – less then 4.71 (low level of p16INK4a mRNA levels in 
PBTLs) and equal or greater than 4.71 relative levels (p16INK4a mRNA levels in PBTLs), 
the inference has not changed for length of hospital stay (HR 1.39, 95% CI 0.72-2.68, 
p=0.33) or length of ICU stay (HR 0.76, 95% CI 0.37-1.56, p=0.46) comparing group with 
high level of p16INK4a mRNA levels in PBTLs to a group with low levels p16INK4a mRNA 
levels in PBTLs.
When we censored the longest hospital discharge day at 15 days and ICU discharge hour at 
122 hours (to assess influence of the outlying points), the inference has not changed either 
for hospital length of stay (HR 1.20, 95% CI 0.92-1.54, p=0.18) or ICU length of stay (HR 
0.86, 95% CI 0.64-1.15, p=0.31).
4. Discussion
Our study is the first one to evaluate clinical utility of p16INK4a mRNA levels in PBTLs in 
cardiac surgical patient population. It showed that p16INK4a mRNA levels in PBTLs in 
patients undergoing CAB are associated with chronologic age. P16INK4a mRNA levels in 
PBTLs did not associate with frailty score and with p16 protein levels in blood vessels, 
vascular stiffness expressed by augmentation index, ScO2. In secondary analyses, p16INK4a 
mRNA levels in PBTLs were associated with serum levels of IL-6, a marker of aging and 
frailty (Taaffe 2000, Cesari 2004, Ferrucci 2005, Maggio 2006, Singh 2011) 37-41Finally, 
there were no association between p16INK4a mRNA levels in PBTLs and postoperative 
length of stay in the hospital or ICU after CAB in older adults.
Our results are consistent with previous report showing association of p16INK4a mRNA 
levels in PBTLs with chronologic age and IL-6 levels 29; however, we were unable to 
demonstrate association with smoking or exercise history in our patient population. Our 
results are different from previous reports of using pretransplant p16INK4a mRNA levels 
from donor kidney biopsies to predict clinical outcomes (McGlynn 2009; Koppelstaetter 
2008; Gingell-Littlejohn 2013) 26-28. In kidney transplantation, p16INK4a mRNA levels 
turned to be one of the best predictors of kidney function at 1 year. Importantly, telomere 
length performed not as well compared to p16INK4a mRNA levels, emphasizing that 
p16INK4a mRNA levels in pretransplant kidney biopsies is a better predictor of outcomes. 
Compared to these reports, we evaluated p16INK4a mRNA levels in PBTLs, focusing rather 
on the entire organism; thus, evaluating more complex clinical outcomes such as length of 
stay in the hospital and in ICU. The lack of apparent associations of p16INK4a mRNA levels 
in PBTLs with frailty, vascular stiffness and p16 protein levels in blood vessels and duration 
of stay in the hospital and ICU in our study could be partially explained by insufficient 
power to detect differences in our patient population, as well by very complex physiology of 
aging and influence of multiple factors on p16INK4a mRNA levels in PBTLs, which are not 
entirely established. Furthermore, medical management of acute coronary artery disease 
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limits measuring frailty in this patient population, when patients are prescribed strict bed 
rest. Even though our sample size provided adequate power to detect moderately extended 
length of stay among persons with higher p16INK4a mRNA levels, the direction of the 
association of p16INK4a mRNA levels in PBTLs with length of hospital stay was the 
opposite to the expected (8.1±4.8 days for the group with low p16INK4a mRNA levels in 
PBTLs versus 6.8±2.8 days for the group with high p16INK4a mRNA levels in PBTLs). 
More importantly, this pilot study achieved our main goals: it confirmed that we can 
successfully recruit patients with based on our inclusion/ exclusion criteria, confirmed that 
they would consent to an aging biomarker study, learned how to isolate T-cells successfully, 
learned what p16INK4a in PBTLs will be like in this population (since they are not healthy 
donors and we did not know how p16 INK4a in PBTLs is affected in this population).
Of note, in this report, a 70-year-old patient has on average a p16INK4a mRNA levels in 
PBTLs of ~4; while p16 level in PBTLs for the same age individual was on average ~7 in 
the original report 29. The difference in reported values is because of a different equation 
that was used to convert Ct values into reported log2 p16INK4a mRNA levels in PBTLs in 
this report and the values are otherwise consistent with previous studies (Sharpless, personal 
communications).
We described differential expression of p16 protein in aorta and LIMA arterial vessels. We 
observed significantly higher levels of p16 in aortic tissue compared to LIMA. This result 
could reflect different rate of aging across different arterial vascular beds, and could explain 
why results of coronary revascularization with LIMA are successful. When taken together 
with p16INK4a mRNA levels in PBTLs, these results highlight heterogeneity of senescence 
across tissues. The main limitation of our methodology is that we measured p16 protein in 
the entire vascular tissue, and we are unable to tell whether endothelium or smooth muscle is 
responsible for the reported result. Interpretation of findings is further complicated by lack 
of control group without CAD. This is justifiable, however, due to invasiveness of vascular 
tissue collection, whereas CAB provides with the unique opportunity to harvest vascular 
tissue. Whether differential levels of senescence in vascular beds play role in vascular 
pathology associated with aging deserves additional investigation.
Our study has several limitations. First, limited number of patients undergoing CAB 
procedure compared to the entire population of older adults may threaten generalizability of 
our findings. However, the design of our study evaluating performance of p16INK4a mRNA 
levels in PBTLs using baseline measurements prior to surgical insult is robust to represent 
older adults with the burden of CAD. Second, we focused only on one biomarker of 
senescence, p16INK4a mRNA levels in PBTLs, which reflects telomere-independent pathway 
of senescence in lymphocytes, as due to insufficient number of viable PBTLs in stored 
samples we were unable to process our samples for telomere length. Evaluation of telomere 
length and telomerase activity in T-lymphocytes, as well as changes in cellular composition 
of the immune system with aging would allow more comprehensive picture of the immune 
system involvement in determining outcomes of surgical procedures. Third, our study has 
low power to detect difference between groups with levels of p16INK4a mRNA levels in 
PBTLs above and below the median. Finally, we evaluated length of hospital stay as the 
primary outcome of interest. It is a complex outcome, which depends on multiple clinical 
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variables as well as administrative decisions, and future investigation will need to focus on 
outcomes more directly related to function of the immune system in perioperative period: 
infectious complications, deep venous thrombosis, and renal failure.
5. Conclusions
Although p16INK4a mRNA levels in PBTLs were significantly correlated with chronologic 
age in older adults undergoing CAB, these levels did not predict any adverse outcomes in 
this population. In addition, p16INK4a mRNA levels in PBTLs did not correlate with p16 
levels in LIMA or in aorta tissue within the same individual, possibly suggesting a tissue 
specific difference in rate of senescence. Given this, evaluation of p16INK4a mRNA levels in 
PBTLs and other tissues as a predictor of outcomes after surgical procedures may warrant 
further investigation in conjunction with other markers of senescence.
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Highlights
• CAB is a commonly performed surgical procedure in older adults
• First prospective study of senescence marker p16INK4a in patients undergoing 
coronary artery bypass (CAB)
• Preoperative mRNA levels of p16INK4a in peripheral blood T-lymphocytes 
(PBTL) correlate with chronological age and interleukin-6 levels in older adults 
with coronary artery disease
• p16INK4a mRNA levels in PBTLs are not associated with frailty, cerebral 
oxygen saturation, aortic and left internal mammary artery p16INK4a protein 
levels, and augmentation index
• p16INK4a mRNA levels in PBTLs do not predict duration of hospital or ICU stay 
after CAB
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Figure 1. 
Western Blot analysis of p16 protein levels in aortic tissue (labeled as aorta) and left internal 
mammary artery (labeled as LIMA). The internal standard is marked at 18 kDa and 
corresponds to recombinant human protein p16, Novus Biologicals, LLC (Littleton CO); the 
lines under corresponding numbers represent p16 protein, with darker lines corresponding to 
higher levels of p16 protein. Expression of p16 protein in the aortic tissue is substantially 
higher compared to LIMA.
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Figure 2. 
Study Flow. The consort diagram for the study shows number of evaluable patients at each 
step. 262 patients were screened for study participation, 178 were identified as eligible based 
on inclusion/exclusion criteria, 60 patients consented and 55 were analyzed. Results from 
the baseline p16INK4a mRNA levels in PBTLs (peripheral blood T-lymphocytes) were not 
available for 8 out of 55 patients. These 8 patients were excluded from the paired analysis of 
p16 expression and other aging markers or hospital and ICU (Intensive Care Unit) stay.
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Figure 3. 
Association of p16INK4a mRNA levels in PBTLs (peripheral blood T-lymphocytes) with 
other markers of aging: (a) Chronologic age; (b) Ratio of p16 protein level in LIMA (left 
internal mammary artery) versus p16 protein level in aorta; (c) Augmentation index; (d) 
Cerebral oximetry; (e) Exercise intensity; (f) Smoking; (g) Interleukin 6 levels. Dots indicate 
individual data, red line is a line from univariate linear regression of p16INK4a mRNA levels 
in PBTLs on variables mentioned in (a)-(f). Figures (a)-(d) reflect a priori analyses, figures 
(e)-(g) reflect secondary analyses. Correlation coefficients (r) and p-values are provided for 
each marker of aging in association with p16INK4a mRNA levels in PBTLs; p-value<0.05 
was considered significant.
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Figure 4. 
Box and whiskers plot of p16INK4a mRNA levels in PBTLs among nonfrail, prefrail and 
frail older adults undergoing CAB (coronary artery bypass). The box demonstrates the 
median value and interquartile range, whereas whiskers demonstrate upper and lower limits 
of p16INK4a mRNA levels in PBTLs (peripheral blood T-lymphocytes) among groups within 
calculated fences.
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Table 1
Characteristics of Analyzed Patients Undergoing Coronary Artery Bypass Surgery during the Study Period
Variable Value*
Age, in years 63.5 (56-81)
Gender, n (%)
    Males 41 (74.55)
    Females 14 (25.45)
Race, n (%)
    Caucasian 47 (85.45)
    African-American 5 (9.09)
    Other 3 (5.46)
P16 mRNA levels in PBTLs (log2-transformed) 4.71 (1.10-6.82)
Baseline P16 mRNA levels in PBTLs, n (%)
    < 4.71 log2-transformed p16INK4a levels 23 (41.82)
    ≥ 4.71 log2-transformed p16INK4a levels 24 (43.64)
    Missing 8 (14.55)
Baseline p16 protein level in LIMA/ p16 protein level in aorta 0.49 (0.26-1.05)
IL-6 levels, in pg/ml 2.66 (0.59-18.48)
Cerebral oximetry, in % 63.5 (39-80)
Augmentation index, in % 26 (5-79)
Charlson comorbidity index 2 (0-12)
Myocardial infarction, n (%) 12 (21.82)
Congestive heart failure, n (%) 2 (3.64)
Chronic pulmonary disease, n (%) 9 (16.36)
Diabetes mellitus, n (%) 19 (34.55)
Moderate or severe renal disease, n (%) 3 (5.45)
Baseline Frailty, n (%)
    Non-frail 10 (18.18)
    Prefrail 28 (50.91)
    Frail 17 (30.91)
Smoking, n (%)
    ≤ 5 pack-years 24 (43.64)
    > 5 pack-years 31 (56.36)
Exercise, n (%)
    ≤ 240 minutes/ month 32 (58.18)
    > 240 minutes/ month 23 (41.82)
Duration of hospital stay, days 6 (3-27)
Duration of ICU stay, hours 33 (7-174)
Abbreviations: PBTLs Peripheral Blood T-Lymphocytes; LIMA Left Internal Mammary Artery; IL-6 Interleukin 6; ICU Intensive Care Unit
*Continuous variables are presented as median (range), and categorical variables are presented as number of participants (%)
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Table 2
Results of linear regression analyses of p16INK4a mRNA levels in PBTLs on other markers of age
Predictors Univariate analyses, estimate (95% CI) *Multivariable analyses, estimate (95% 
CI)
A priori analyses
Chronologic age, years 0.07 (0.02-0.12)** -
P16 protein level in LIMA/ p16 protein level in aorta 0.56 (-1.64-2.77) 0.31 (−1.87-2.49)
Augmentation index, % 0.00 (−0.02-0.02) −0.01 (−0.02-0.01)
Cerebral oximetry, % 0.03 (−0.01-0.08) 0.04 (0.00-0.07)
Secondary analyses
Chronologic age, years 0.07 (0.02-0.12)** 0.06 (0.01-0.11)**
Interleukin 6 levels, pg/ml 0.11 (0.03-0.20)** 0.09 (0.01-0.18)**
Exercise
    > 240 min/month REF -
    ≤ 240 min/month 0.01 (−0.74-0.76) 0.11 (−0.58-0.79)
Smoking
    ≤ 5 pack-years REF -
    > 5 pack-years 0.06 (−0.68-0.80) 0.01 (−0.67-0.68)
Abbreviations: CI, Confidence Interval; LIMA, Left Internal Mammary Artery; REF, reference value
*
In a priori multivariable analyses adjustments were made for chronologic age; in secondary multivariable analyses variables included interleukin 
6 levels, exercise, smoking and chronologic age
**
Indicates significant results based on evaluation of CI
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Table 3
Frailty status according to p16 levels in PBTLs
Phenotype *Univariate analysis, RRR (95% CI) **Multivariable analysis, RRR (95% CI)
Nonfrail REF REF
Prefrail 0.97 (0.52-1.80) 1.06 (0.53-2.12)
Frail 0.92 (0.48-1.76) 0.78 (0.38-1.60)
Abbreviations: RRR, Relative Risk Ratio; CI, Confidence Interval; REF, Reference value
*
Multinomial regression was performed, results are reported as RRR (95% CI)
**Adjustments were made for chronologic age
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Table 4
Duration of hospital and ICU length of stay according to increasing p16 levels in PBTLs
*Univariate analysis, HR (95% CI) **Multivariable analysis, HR (95% CI)
Duration of stay in the hospital 1.07 (0.87-1.32) 1.10 (0.87-1.40)
Duration of stay in ICU 1.13 (0.90-1.43) 0.98 (0.74-1.28)
Abbreviations: HR, Hazard Ratio; CI, Confidence Interval; ICU, Intensive Care Unit
*Cox proportional hazards regression was performed, with results reported as HR (95% CI) of discharge from the hospital or ICU
**Adjustments were made for chronologic age, frailty status and Charlson comorbidity index
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